What is Cellmid?
Founded in 2004 and headquartered in Sydney, Australia, Cellmid is a life sciences company dedicated to the research, development, and commercialization of innovative diagnostic and therapeutic products. The company's focus areas include cancer and various chronic inflammatory conditions, with operations spanning Australia, the United States, and Japan. Cellmid's strategic direction is geared towards advancing its pipeline and expanding its market reach.
How much funding has Cellmid raised?
Cellmid has raised a total of $7M across 2 funding rounds:
Debt
$1M
Share Placement
$6M
Debt (2015): $1M with participation from Platinum Road
Share Placement (2020): $6M, investors not publicly disclosed
Key Investors in Cellmid
Platinum Road
Platinum Road, operating within the Australian financial sector, likely provides strategic debt financing and investment opportunities to growing companies.
What's next for Cellmid?
The recent major strategic investment provides Cellmid with substantial resources to accelerate its growth and development initiatives. This capital infusion is expected to fuel further research and commercialization efforts, potentially leading to expanded product offerings and market penetration in key regions. The company's trajectory suggests a focus on scaling operations and solidifying its position in the competitive life sciences landscape.
See full Cellmid company page
